Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
16 participants
INTERVENTIONAL
2004-11-30
2005-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
LAF 237 is an inhibitor of DPP-4 that has been shown to increase meal-stimulated levels of intact GLP-1 in animals and patients with T2DM..
The purpose of the current study is to explore the acute effects of LAF237 on the rate of appearance and disappearance of glucose in type 2 diabetics. Secondary objectives include the effect on FPG, insulin secretion rates, glucagon and FFA levels, and rate of glucose entry from the GI tract.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
At screening, patients will begin a weight maintaining diet containing 50% carbohydrates, 30% protein and 20% fat.
Within 7 days from screening patients will be scheduled for treatment 1. Patients will begin a 10-hour overnight fast on Day -1 at \~21h00. Patients will be admitted to GCRC next day. Fasting plasma glucose sample will be drawn and following this the patient will be served a standard breakfast containing 1/5 of their caloric allotment (50% carbohydrates, 30% protein and 20% fat). At noon patient will be fed a standard lunch containing 2/5 of their caloric allotment (50% carbohydrates, 30% protein and 20% fat). At 14h30 (-210) an infusion of 3-3H glucose will be started and continued until 08h00 next day (20 µCi x FPG/100 continuous, 0.20/min). At 17h30 (-30) patients will ingest 100 mg of LAF237 or placebo with 200 ml of water. At 18h00 (time zero) patients will be served a dinner (2/5 of their caloric allotment). The carbohydrates (glucose) in the meal will be labeled with 75 µCi of \[1-14C\]-glucose.
At -60, -50, -40, -35, -30, -20, -10, -5, and 0 minutes before dinner plasma samples for determination of glucose, insulin, C-peptide, glucagons, GLP-1, GIP, FFA, lactate, and amino acid concentrations and 3-3H glucose radioactivity will be drawn. Following dinner, further blood samples will be drawn every 15 minutes for 3.5 hours (18h00-21h30) and every 30 minutes for the next 10.5 hours (22h00-08h00 Day 2). Post dinner samples will be analyzed for the above parameter as well as for 14C glucose radioactivity. At 08h00 on Day 2, both catheters will be removed and the patients will be fed breakfast and then released from the site.
In addition to blood samples, urine from dinner time until 08h00 on Day 2 will be collected.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
LAF 237
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Time of diagnosis: within 6 months prior to screening, or 1 month prior to screening with no detectable anti-GAD Abs
3. Normal physical exam, EKG, blood tests, and urinalysis
4. HbA1c=7-11% at screening
5. FPG=160-280 mg/dl at screening
6. Diabetes controlled by diet and exercise alone or by stable dosage of metformin or sulfonylurea
7. BMI=22-45 kg/m2 and with a stable (+/- 2.5 kg) weight for the last 6 months
8. Compliant to study requirements \& written consent.
Exclusion Criteria
2. History of: type 1 DM, pancreatic injury, secondary diabetes (Cushing, acromegaly), acute metabolic complications (ketoacidosis or hyperosmolar state) within the past 6 months, torsades des pointes, ventricular tachycardia or ventricular fibrillation
3. Any of the following within the past 6 months: MI, CABG, unstable angina
4. ECG abnormalities: second degree AV block (Mobitz 1 and 2), third degree AV block, prolonged QTc (\>450 ms)
5. Use of the following medications: class Ia ,Ib, Ic or III antiarrhythmics, insulin, thiazolidinediones, corticosteroids
6. Investigational drug treatment within 4 weeks prior to screening unless local health authority guidelines mandate a longer period
7. Fasting triglycerides \>700 mg/dl at screening
8. Diabetic complications
9. Renal disease (creatinine \>1.5 mg/dl-males or \>1.4 mg/dl-female), renal failure, hepatic dysfunction, thyrotoxicosis
10. History of gastrointestinal surgery (partial bowel resections, partial gastric resections)
11. Donation of one unit of blood within 2 weeks or transfusion within 8 weeks prior to screening
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novartis
INDUSTRY
The University of Texas Health Science Center at San Antonio
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ralph A DeFronzo, MD
Role: PRINCIPAL_INVESTIGATOR
University of Texas
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Audie L Murphy VA Hospital
San Antonio, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CLAF237A2346
Identifier Type: -
Identifier Source: org_study_id